UroGen Pharma to Present at H.C. Wainwright BioConnect Conference

Rhea-AI Summary

UroGen Pharma Ltd. (Nasdaq: URGN) will participate in a fireside chat at the H.C. Wainwright BioConnect Conference on May 2, 2023 from 10:00 AM ET. This event aims to showcase UroGen's dedication to developing innovative treatments for urothelial and specialty cancers.

A live audio webcast will be accessible via the company's investor website, with a replay available for approximately 30 days post-event.

UroGen specializes in proprietary technologies, notably RTGel®, a sustained-release hydrogel platform that enhances drug efficacy in treating urinary tract conditions. Its products, including Jelmyto® and investigational UGN-102, aim to non-surgically ablate tumors. UroGen is based in Princeton, NJ, and operates in Israel.

- Fireside Chat May 2, 2023 from 10:00 – 10:30 AM ET -

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a fireside chat at the upcoming H.C. Wainwright BioConnect Conference on May 2, 2023 at 10:00 AM ET.

A live audio webcast will be available in the "Events and Presentations" section of UroGen’s investor website. A replay will be available for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Jelmyto® (mitomycin) for pyelocaliceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005188/en/

INVESTOR CONTACT:

Vincent Perrone

Senior Director, Investor Relations

vincent.perrone@urogen.com

609-460-3588

MEDIA CONTACT:

Cindy Romano

UroGen Corporate Communications

cindy.romano@urogen.com

908-963-7827

Source: UroGen Pharma Ltd.

FAQ

What is the date and time of UroGen Pharma's participation in the H.C. Wainwright BioConnect Conference?

UroGen Pharma will participate in the H.C. Wainwright BioConnect Conference on May 2, 2023, from 10:00 AM ET.

How can I access the live webcast for UroGen Pharma's fireside chat?

The live audio webcast for UroGen Pharma's fireside chat can be accessed on their investor website under the Events and Presentations section.

What innovative technologies does UroGen Pharma develop?

UroGen Pharma develops proprietary technologies, including RTGel®, a sustained-release hydrogel platform designed to improve treatments for urothelial and specialty cancers.

What are UroGen Pharma's products for treating tumors?

UroGen Pharma's products include Jelmyto® (mitomycin) for pyelocaliceal solution and investigational UGN-102 (mitomycin) for intravesical solution, both designed for non-surgical tumor ablation.

Where is UroGen Pharma headquartered?

UroGen Pharma is headquartered in Princeton, NJ, with operations in Israel.